

Phillip Wong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5439881/publications.pdf>

Version: 2024-02-01

28
papers

16,373
citations

257357

24
h-index

526166

27
g-index

28
all docs

28
docs citations

28
times ranked

23940
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	5.8	37
2	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/âˆ™ trastuzumab in patients with breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2022, 8, 50.	2.3	17
3	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	3.2	15
4	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repairâ€“proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	3.2	51
5	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. <i>Nature Medicine</i> , 2021, 27, 1646-1654.	15.2	65
6	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
7	Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 5609-5620.	3.2	32
8	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	15.2	216
9	A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3193-3201.	3.2	27
10	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	7.0	217
11	PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. <i>Cancer Cell</i> , 2018, 34, 775-791.e3.	7.7	170
12	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017, 73, 61-70.	1.3	88
13	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65.	13.7	1,280
14	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	3.2	146
15	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016, 22, 5729-5737.	3.2	175
16	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 835-844.	1.6	138
17	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
18	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459

#	ARTICLE	IF	CITATIONS
19	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. , 2015, 3, 23.		190
20	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
21	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	13.9	3,753
22	Rapid Development of T Cell Memory. Journal of Immunology, 2004, 172, 7239-7245.	0.4	55
23	Disparate In Vitro and In Vivo Requirements for IL-2 During Antigen-Independent CD8 T Cell Expansion. Journal of Immunology, 2004, 172, 2171-2176.	0.4	32
24	Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood, 2004, 104, 2397-2402.	0.6	34
25	CD8 T CELLRESPONSES TOINFECTIOUSPATHOGENS. Annual Review of Immunology, 2003, 21, 29-70.	9.5	367
26	Feedback Regulation of Pathogen-Specific T Cell Priming. Immunity, 2003, 18, 499-511.	6.6	166
27	In Vivo Depletion of CD11c+ Dendritic Cells Abrogates Priming of CD8+ T Cells by Exogenous Cell-Associated Antigens. Immunity, 2002, 17, 211-220.	6.6	1,579
28	Cutting Edge: Antigen-Independent CD8 T Cell Proliferation. Journal of Immunology, 2001, 166, 5864-5868.	0.4	242